Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Co-codamol 30mg/500mg tablets
0407010F0AAAHAH
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 459,960 |
|
Zapain 30mg/500mg tablets
0407010F0BSAAAH
|
Zapain | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 252,152 |
|
Co-codamol 15mg/500mg tablets
0407010F0AAAKAK
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 220,731 |
|
Co-codamol 8mg/500mg tablets
0407010F0AAAAAA
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 189,019 |
|
Co-codamol 30mg/500mg capsules
0407010F0AAADAD
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 164,855 |
|
Co-codamol 30mg/500mg effervescent tablets
0407010F0AAAFAF
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 85,588 |
|
Zapain 30mg/500mg capsules
0407010F0BSABAD
|
Zapain | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 42,237 |
|
Co-codamol 8mg/500mg effervescent tablets
0407010F0AAACAC
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 38,873 |
|
Co-codamol 15mg/500mg capsules
0407010F0AAAVAV
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 28,039 |
|
Co-codamol 8mg/500mg capsules
0407010F0AAABAB
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 22,063 |
|
Emcozin 30mg/500mg tablets
0407010F0BYAAAH
|
Emcozin | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 14,556 |
|
Solpadol 30mg/500mg caplets
0407010F0BGABAH
|
Solpadol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 13,977 |
|
Solpadol 30mg/500mg effervescent tablets
0407010F0BGAAAF
|
Solpadol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 11,496 |
|
Co-codamol 15mg/500mg effervescent tablets sugar free
0407010F0AAAWAW
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 6,186 |
|
Tylex 30mg/500mg capsules
0407010F0BEAAAD
|
Tylex | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 6,007 |
|
Kapake 30mg/500mg tablets
0407010F0BHAAAH
|
Kapake | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 2,889 |
|
Migraleve Yellow tablets
0407010F0BXAAAA
|
Migraleve (Analgesic) | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 2,514 |
|
Solpadol 30mg/500mg capsules
0407010F0BGACAD
|
Solpadol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 1,693 |
|
Kapake 30mg/500mg capsules
0407010F0BHADAD
|
Kapake | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 1,313 |
|
Co-codamol 8mg/500mg effervescent tablets sugar free
0407010F0AABABA
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 1,288 |
|
Codipar 15mg/500mg capsules
0407010F0BVABAV
|
Codipar | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 1,160 |
|
Co-codamol 12.8mg/500mg tablets
0407010F0AAAPAP
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 874 |
|
Codipar 15mg/500mg tablets
0407010F0BVAAAK
|
Codipar | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 841 |
|
Solpadeine Max 12.8mg/500mg tablets
0407010F0BPAAAP
|
Solpadeine Max | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 204 |
|
Co-codamol 30mg/500mg/5ml oral solution sugar free
0407010F0AAAZAZ
|
Co-codamol | Co-codamol (Codeine phosphate/paracetamol) | Central Nervous System | 89 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.